Form 4: Lyell Immunopharma Director Richard Klausner Acquires 158,000 Shares

Director Richard Klausner reports the acquisition of 158,000 shares of Lyell Immunopharma at an average price of $0.6009.

Summary

• On March 14, 2025, Richard Klausner, a director of Lyell Immunopharma, acquired 158,000 shares of common stock.
• The shares were purchased at a weighted average price of $0.6009, with individual prices ranging from $0.59 to $0.62.
• Following the transaction, Klausner directly owns 2,967,834 shares and indirectly owns 843,365 shares.
• The indirect ownership includes shares held by The Klausner Family Revocable Trust and several Delaware Trusts.

Sentiment

Score: 6

Explanation: Insider buying is generally viewed as a positive sign, but the impact is moderate as it's a single transaction and the overall sentiment depends on the context of the company's performance and industry trends.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions. They are closely watched by investors for signals about management's view of the company's prospects.

Stakeholder Impact

• Shareholders may view the director's stock purchase as a positive indicator of the company's potential.

Key Dates